Skip to main content
OpenTrials
Completed

NCT Number: NCT02641626

Coronariography in OUt of hosPital Cardiac arrEst

Prospective, multicenter, randomized clinical trial. Survivors from an out-of-hospital cardiac arrest (OHCA) without ST segment elevation in their EKG will be recruited. Potentially non-cardiac etiology of the cardiac arrest will be ruled out prior to randomization. Primary goal (treatment): to evaluate the efficacy of urgent vs deferred coronary angiography in survivors from OHCA without ST-segment elevation in the EKG.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital Clínico San Carlos

Madrid, 28040, Spain

About this study

Prospective, multicenter and randomized clinical trial. Survivors from Out-of-Hospital Cardiac Arrest (OHCA) who do not show ST elevation in their EKG will be recruited in the present study. Potentially non-cardiac ethiology of the cardiac arrest will be ruled out prior to randomization. Afterwards, patients will be randomized to emergent or deferred (performed before discharge) coronary angiography. Both groups will receive routine care in the Acute Cardiac Care Unit, including therapeutic hypothermia.

The randomization will be in a 1:1 ratio to urgent or deferred coronary angiography.

The main objective of the study is to compare the effectiveness of an urgent coronary angiography and angioplasty if necessary versus a deferred coronary angiography in survivors from OHCA who after recovery of spontaneous circulation do not fulfill criteria for ST-elevation myocardial infarction.

The primary efficacy endpoint is a composite of in-hospital survival and six-month survival free of severe dependence, which will be evaluated by using the Cerebral Performance Category (CPC) Scale, being good prognosis represented by the categories 1 and 2.The safety endpoint will be a composite of MACE (Major Adverse Cardiac Events) including: death, reinfarction, bleeding or ventricular arrhythmias.

A total of 166 patients will be included. The estimated duration will be 42 months, with a target follow-up of 6 months. Periods will be divided as follows:

  • Inclusion Period (selection of the population and data collection): 36 months.
  • Monitoring, data analysis, statistical and clinical report: 6 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

survivors from out of hospital cardiac arrest who meet all the following criteria:

  • Remain comatose after recovery of spontaneous circulation (ROSC) (Glasgow Coma Scale score equal or less than 8).
  • Show a non-diagnostic electrocardiogram after ROSC (neither ST segment elevation nor left bundle branch block).
  • Prior rule out of an obvious non-cardiac cause of the cardiac arrest (head CT scan and transthoracic echocardiogram).
  • Absence of exclusion criteria.

Exclusion criteria

  • Age <18 years.
  • Pregnant women or women of childbearing age unless they have a negative pregnancy test.
  • Time to return of spontaneous circulation longer than 60 minutes.
  • Non-cardiac etiology of the comatose state: drug overdose, head injury or stroke.
  • Acute myocardial infarction with ST segment elevation or left bundle branch block, because in those patients emergent angiography is mandatory.
  • Hemodynamic instability (refractory cardiogenic shock despite vasoactive drugs or refractory arrhythmias), because in those patients an emergent angiography is mandatory.
  • Known coagulopathy or bleeding.
  • Refusal to participate in the study by the next of kin.

Treatment and study plan

Urgent Coronary Angiography

Procedure

Diagnostic test for the evaluation of the coronary vasculature.

Deferred Coronary Angiography

Procedure

Diagnostic test for the evaluation of the coronary vasculature.

Primary outcomes

  1. Survival with good neurological outcome for activities of daily living (CPC 1-2).

    Time frame: 30 days.

    Survival with good neurological outcome for activities of daily living (CPC 1-2).

  2. Survival with good neurological outcome for activities of daily living (CPC 1-2).

    Time frame: 6 months.

    Survival with good neurological outcome for activities of daily living (CPC 1-2).

  3. MACE: death, myocardial infarction, clinically evident bleeding (BARC> 2) or ventricular arrhythmias.

    Time frame: 30 days.

    MACE: death, myocardial infarction, clinically evident bleeding (BARC> 2) or ventricular arrhythmias.

  4. MACE: death, myocardial infarction, clinically evident bleeding (BARC> 2) or ventricular arrhythmias.

    Time frame: 6 months.

    MACE: death, myocardial infarction, clinically evident bleeding (BARC> 2) or ventricular arrhythmias.

Secondary outcomes

  1. Hospital survival.

    Time frame: 30 days.

    Hospital survival.

  2. Hospital survival.

    Time frame: 6 months.

    Hospital survival.

  3. Neurological outcome assessed by the Cerebral Performance Category (CPC) Scale.

    Time frame: 30 days.

    Neurological outcome assessed by the Cerebral Performance Category (CPC)

  4. Neurological outcome assessed by the Cerebral Performance Category (CPC) Scale.

    Time frame: 6 months.

    Neurological outcome assessed by the Cerebral Performance Category (CPC)

  5. Left ventricular ejection fraction.

    Time frame: 30 days.

    Left ventricular ejection fraction.

  6. Left ventricular ejection fraction.

    Time frame: 6 months.

    Left ventricular ejection fraction.

  7. Infarction size

    Time frame: 30 days.

    Defined by the maximum CPK (creatine phosphokinase) and Troponin.

  8. Vascular complications.

    Time frame: 30 days.

    Vascular complications such as pseudoaneurysms, arteriovenous fistulas, etc

  9. Clinically evident haemorrhagia: BARC> 2

    Time frame: 30 days.

    Clinically evident haemorrhagia: BARC> 2

  10. Sustained ventricular arrythmias or requirement of cardioversion.

    Time frame: 30 days.

    Sustained ventricular arrythmias or requirement of cardioversion.

  11. Renal impairment.

    Time frame: 30 days.

    A 50% increase of serum creatinine over a baseline level or an increase of >0.5 mg/dl

  12. Reinfarction.

    Time frame: 30 days.

    According to the Universal Definition of Acute Myocardial Infarction

  13. Stent Thrombosis

    Time frame: 30 days.

    Defined by the Academic Research Consortium (ARC).

  14. Infections.

    Time frame: 30 days.

    Infections.

  15. Length of intubation.

    Time frame: 30 days.

    Length of intubation.

  16. Length of hospital stay.

    Time frame: 6 months.

    Length of hospital stay.

Sponsors and collaborators

Lead sponsor

Hospital San Carlos, Madrid

Other

Collaborators

  • Complejo Hospitalario Universitario de Santiago
  • Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
  • Germans Trias i Pujol Hospital
  • Hospital Arnau de Vilanova
  • Hospital Clinic of Barcelona
  • Hospital Clínico Universitario de Valladolid
  • Hospital General Universitario Gregorio Marañon
  • Hospital Universitari Joan XXIII de Tarragona.
  • Hospital Universitari de Bellvitge
  • Hospital Universitario Principe de Asturias
  • Hospital Universitario Ramon y Cajal
  • Hospital Universitario Virgen Macarena
  • Hospital Universitario de Canarias
  • Hospital Vall d'Hebron
  • Hospital de Leon
  • Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta

Registry information

Official study title

Randomized Study About the Efficacy of an Urgent Coronariography in Patients With a Non-diagnostic Electrocardiogram Following Out of Hospital Cardiac Arrest.

Acronym: COUPE

Important dates

Study start
2016
Primary completion
2021
Study completion
2021
First posted
Dec 29, 2015
Registry last updated
Aug 30, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.